IART on Nasdaq

INTEGRA LIFESCIENCES HOLDINGS CORP

American surgical and medical instruments and apparatus company.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with MERIT MEDICAL SYSTEMS INC, Penumbra or Teleflex, or pick any stock.

  • TickerIART on Nasdaq
  • IndustrySurgical & Medical Instruments & Apparatus
  • HeadquartersPrinceton, United States
  • Incorporated inDE2
  • Business address1100 Campus Road, Princeton, Nj 085402
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-30.2%Operating margin3
-31.6%Net margin3
1.5%Revenue growth, 20253
-49.5%Return on equity3
0.70×Debt to equity3
-$31.1MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Codman Specialty Surgical brought in 73% of the revenue INTEGRA LIFESCIENCES HOLDINGS CORP broke down this way in fiscal 2025.

  1. Codman Specialty Surgical$1.2B373%up 5% from 2024
  2. Tissue Technologies$434.7M327%down 7% from 2024
Business segments by year
Business segments202320242025
Codman Specialty Surgical$1.1B$1.1B$1.2B
Tissue Technologies$482.6M$466.9M$434.7M

Regions

United States brought in 74% of the revenue INTEGRA LIFESCIENCES HOLDINGS CORP broke down this way in fiscal 2025.

  1. United States$1.2B374%up 1% from 2024
  2. Asia Pacific$189.3M312%up 7% from 2024
  3. Europe$162.7M310%up 3% from 2024
  4. Rest of the World$78.6M35%down 5% from 2024
Regions by year
Regions202320242025
United States$1.1B$1.2B$1.2B
Asia Pacific$193.1M$176.6M$189.3M
Europe$165.2M$158.5M$162.7M
Rest of the World$82.5M$82.7M$78.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue49¢$803.6M
  • Selling, general and admin43¢$699.7M
  • Other costs5¢$84.9M
  • Income tax3¢$47.0M

Out of $1.6B in revenue.3 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending100¢$81.4M
  • Share buybacks0¢$221.0K

Out of $50.4M of cash from operations. Spending exceeded cash from operations; the rest came from savings or borrowing.3

Financial statements

Revenue45673$1.6B in 2025+8% since 2019
0$500.0M$1.0B$1.5B$2.0B2019: $1.5B$1.5B20192020: $1.4B$1.4B2020−10%2021: $1.5B$1.5B2021+12%2022: $1.6B$1.6B2022+1%2023: $1.5B$1.5B2023−1%2024: $1.6B$1.6B2024+4%2025: $1.6B$1.6B2025+2%
Gross profit8$851.0M in 2020−11% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $952.9M$952.9M20192020: $851.0M$851.0M2020−11%
Operating income45673-$493.4M in 2025
-$600.0M-$400.0M-$200.0M0$200.0M$400.0M2019: $93.8M$93.8M20192020: $151.4M$151.4M2020+61%2021: $197.2M$197.2M2021+30%2022: $238.9M$238.9M2022+21%2023: $111.5M$111.5M2023−53%2024: $28.4M$28.4M2024−75%2025: -$493.4M-$493.4M2025
Net income45673-$516.5M in 2025
-$600.0M-$400.0M-$200.0M0$200.0M2019: $50.2M$50.2M20192020: $133.9M$133.9M2020+167%2021: $169.1M$169.1M2021+26%2022: $180.6M$180.6M2022+7%2023: $67.7M$67.7M2023−62%2024: -$6.9M-$6.9M20242025: -$516.5M-$516.5M2025+7338%

Every line of the income statement in the latest annual report, as filed.3

Period ending2025-12-312024-12-312023-12-31
Total Revenue, net$1.6B$1.6B$1.5B
Cost of goods sold$803.6M$728.5M$656.8M
Research and development$99.0M$115.4M$104.2M
Selling, general and administrative$699.7M$717.0M$656.6M
Intangible asset amortization$15.0M$21.3M$12.4M
Goodwill impairment charge$511.4M$0$0
Total costs and expenses$2.1B$1.6B$1.4B
Operating (loss) income-$493.4M$28.4M$111.5M
Interest income$18.5M$20.0M$17.2M
Interest expense-$86.3M-$70.6M-$51.4M
Other (expense) income, net-$2.4M$3.9M$3.7M
(Loss) income before income taxes-$563.5M-$18.2M$81.1M
(Benefit) provision for income taxes-$47.0M-$11.3M$13.3M
Net (loss) income-$516.5M-$6.9M$67.7M
Basic (in dollars per share)-$6.74-$0.09$0.85
Diluted (in dollars per share)-$6.74-$0.09$0.84
Basic (in shares)76.7M shares77.0M shares80.1M shares
Diluted (in shares)76.7M shares77.0M shares80.3M shares

Compare INTEGRA LIFESCIENCES HOLDINGS CORP with another company

Leadership

Who has led INTEGRA LIFESCIENCES HOLDINGS CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stuart Essig2006–2012
  2. Peter Arduini2012–2021
  3. Witte Jan De2021–2024
  4. Mojdeh Poul2025–now

Chair

  1. Stuart Essig2012–now

President

  1. Stuart Essig2006–2010
  2. Peter Arduini2010–2021
  3. Witte Jan De2021–2024
  4. Mojdeh Poul2025–now

Chief financial officer

  1. Maureen B. Bellantoni2006–2007
  2. John B. Henneman Iii.2007–2014
  3. Glenn Coleman2014–2019
  4. Carrie L. Anderson2019–2022
  5. Lea Daniels Knight2023–now

Chief operating officer

  1. Gerard S. Carlozzi2006–2010
  2. Peter Arduini2010
  3. Glenn Coleman2019–2022
2010201520202025
Board members and other officers (38)

Former names

  • INTEGRA LIFESCIENCES CORPNov 14, 1996 to Mar 31, 19992

Timeline

  1. Jan 7, 2025New chief executive Mojdeh Poul becomes CEO12
  2. Dec 10, 2021New chief executive Witte Jan De becomes CEO13
  3. Jan 4, 2012New chief executive Peter Arduini becomes CEO14
  4. Jan 5, 2006New chief executive Stuart Essig becomes CEO15
  5. Jun 19, 1989Founded INTEGRA LIFESCIENCES HOLDINGS CORP is founded59

Recent filings

  1. Oct 13, 20263
  2. Oct 9, 20268-K
  3. Oct 2, 20268-K
  4. Sep 28, 20263
  5. Sep 8, 20268-K
  6. Sep 4, 20264
  7. Aug 13, 2026SCHEDULE 13G/A
  8. Jul 31, 2026SCHEDULE 13G
  9. Jul 29, 20268-K
  10. Jul 29, 202610-Q
  11. Jul 6, 20264
  12. Jul 6, 20264
  13. Jul 6, 20264
  14. Jul 6, 20264
  15. Jun 3, 20264

Every filing from the last three years, summarized. The full record is on SEC EDGAR.1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59